The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Sophia Frentzas
No Relationships to Disclose
 
Catherine M. Shannon
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - AstraZeneca; Roche
Travel, Accommodations, Expenses - Novartis
 
Katharine Cuff
Stock and Other Ownership Interests - Sonic Healthcare
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Richard Wilhelm Eek
Stock and Other Ownership Interests - Gilead Sciences; Novartis
 
George Thomas Budd
Honoraria - Deciphera
Consulting or Advisory Role - Deciphera; Epic Sciences
Speakers' Bureau - Deciphera
Research Funding - Ambrx (Inst); Daiichi Sankyo/Lilly (Inst); Genentech/Roche (Inst); TRACON Pharma (Inst)
 
Amelia McCartney
No Relationships to Disclose
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Janice M. Lu
Honoraria - Daiichi Sankyo; Novartis; Pfizer; Puma Biotechnology
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Novartis; Pfizer; Puma Biotechnology
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis; Pfizer
 
Jian Zhang
No Relationships to Disclose
 
Dongmei Ji
No Relationships to Disclose
 
Weina Shen
No Relationships to Disclose
 
Matt Li
Employment - Ambrx; Bristol-Myers Squibb (I); Daiichi Sankyo Inc.
Stock and Other Ownership Interests - Ambrx; Bristol-Myers Squibb (I)
 
Jinchun Yan
Employment - Ambrx
Leadership - Ambrx
Stock and Other Ownership Interests - Ambrx; BMS
 
Gang Xia
No Relationships to Disclose
 
Yanping Ji
No Relationships to Disclose
 
Sulan Yao
Employment - Ambryx
Stock and Other Ownership Interests - Ambryx
Honoraria - Ambrx
Travel, Accommodations, Expenses - Ambryx
Other Relationship - Ambryx
 
Gaozhun Xiong
No Relationships to Disclose
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis